|
1
|
Eisemann N, Waldmann A, Geller AC,
Weinstock MA, Volkmer B, Greinert R, Breitbart EW and Katalinic A:
Non-melanoma skin cancer incidence and impact of skin cancer
screening on incidence. J Invest Dermatol. 134:43–50. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Que SKT, Zwald FO and Schmults CD:
Cutaneous squamous cell carcinoma: Incidence, risk factors,
diagnosis, and staging. J Am Acad Dermatol. 78:237–247. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Muzic JG, Schmitt AR, Wright AC, Alniemi
DT, Zubair AS, Lourido Olazagasti JM, Seda Sosa IM, Weaver AL and
Baum CL: Incidence and trends of basal cell carcinoma and cutaneous
squamous cell carcinoma: A population-based study in olmsted
county, minnesota, 2000 to 2010. Mayo Clin Proc. 92:890–898. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burton KA, Ashack KA and Khachemoune A:
Cutaneous squamous cell carcinoma: A review of high-risk and
metastatic disease. Am J Clin Dermatol. 17:491–508. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Diepgen T, Fartasch M, Drexler H and
Schmitt J: Occupational skin cancer induced by ultraviolet
radiation and its prevention. Br J Dermatol. 167 Suppl 2:S76–S84.
2012. View Article : Google Scholar
|
|
6
|
Boeckx C, Baay M, Wouters A, Specenier P,
Vermorken JB, Peeters M and Lardon F: Anti-epidermal growth factor
receptor therapy in head and neck squamous cell carcinoma: Focus on
potential molecular mechanisms of drug resistance. Oncologist.
18:850–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dotto GP and Rustgi AK: Squamous cell
cancers: A unified perspective on biology and genetics. Cancer
Cell. 29:622–637. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moosavinasab S, Patterson J, Strouse R,
Rastegar-Mojarad M, Regan K, Payne PR, Huang Y and Lin SM: ‘RE:fine
drugs’: An interactive dashboard to access drug repurposing
opportunities. Database (Oxford). 2016:pii: baw0832016. View Article : Google Scholar
|
|
9
|
Andronis C, Sharma A, Virvilis V,
Deftereos S and Persidis A: Literature mining, ontologies and
information visualization for drug repurposing. Brief Bioinform.
12:357–368. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Beck TN, Golemis EA and
Serebriiskii IG: Integrating in silico resources to map a signaling
network. Methods Mol Biol. 1101:197–245. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Baran J, Gerner M, Haeussler M, Nenadic G
and Bergman CM: pubmed2ensembl: A resource for mining the
biological literature on genes. PLoS One. 6:e247162011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carmona-Saez P, Chagoyen M, Tirado F,
Carazo JM and Pascual-Montano A: GENECODIS: A web-based tool for
finding significant concurrent annotations in gene lists. Genome
Biol. 8:R32007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su G, Morris JH, Demchak B and Bader GD:
Biological network exploration with Cytoscape 3. Curr Protoc
Bioinformatics. 47:8.13.1–24. 2014. View Article : Google Scholar
|
|
15
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wagner AH, Coffman AC, Ainscough BJ, Spies
NC, Skidmore ZL, Campbell KM, Krysiak K, Pan D, McMichael JF,
Eldred JM, et al: DGIdb 2.0: Mining clinically relevant drug-gene
interactions. Nucleic Acids Res. 44:D1036–D1044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ribas A and Flaherty KT: BRAF targeted
therapy changes the treatment paradigm in melanoma. Nat Rev Clin
Oncol. 8:426–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stratigos A, Garbe C, Lebbe C, Malvehy J,
del Marmol V, Pehamberger H, Peris K, Becker JC, Zalaudek I, Saiag
P, et al: Diagnosis and treatment of invasive squamous cell
carcinoma of the skin: European consensus-based interdisciplinary
guideline. Eur J Cancer. 51:1989–2007. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wright TJ, McKee C, Birch-Machin MA, Ellis
R, Armstrong JL and Lovat PE: Increasing the therapeutic efficacy
of docetaxel for cutaneous squamous cell carcinoma through the
combined inhibition of phosphatidylinositol 3-kinase/AKT signalling
and autophagy. Clin Exp Dermatol. 38:421–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wood JP, Smith AJ, Bowman KJ, Thomas AL
and Jones GD: Comet assay measures of DNA damage as biomarkers of
irinotecan response in colorectal cancer in vitro and in vivo.
Cancer Med. 4:1309–1321. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cogle CR, Scott BL, Boyd T and
Garcia-Manero G: Oral azacitidine (CC-486) for the treatment of
myelodysplastic syndromes and acute myeloid leukemia. Oncologist.
20:1404–1412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maubec E, Petrow P, Scheer-Senyarich I,
Duvillard P, Lacroix L, Gelly J, Certain A, Duval X, Crickx B,
Buffard V, et al: Phase II study of cetuximab as first-line
single-drug therapy in patients with unresectable squamous cell
carcinoma of the skin. J Clin Oncol. 29:3419–3426. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Balduzzi S, Mantarro S, Guarneri V,
Tagliabue L, Pistotti V, Moja L and D'Amico R:
Trastuzumab-containing regimens for metastatic breast cancer.
Cochrane Database Syst Rev: CD006242. 2014. View Article : Google Scholar
|
|
24
|
Harbeck N, Beckmann MW, Rody A,
Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I,
Heinrich G, et al: HER2 dimerization inhibitor pertuzumab-mode of
action and clinical data in breast cancer. Breast Care (Basel).
8:49–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim ES and Dhillon S: Ibrutinib: A review
of its use in patients with mantle cell lymphoma or chronic
lymphocytic leukaemia. Drugs. 75:769–776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang K and Fu LW: Mechanisms of resistance
to BCR-ABL TKIs and the therapeutic strategies: A review. Crit Rev
Oncol Hematol. 93:277–292. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roberts PJ: Clinical use of crizotinib for
the treatment of non-small cell lung cancer. Biologics. 7:91–101.
2013.PubMed/NCBI
|
|
28
|
Hahn KA, Ogilvie G, Rusk T, Devauchelle P,
Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini
F, et al: Masitinib is safe and effective for the treatment of
canine mast cell tumors. J Vet Intern Med. 22:1301–1309. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gan HK, Seruga B and Knox JJ: Sunitinib in
solid tumors. Expert Opin Investig Drugs. 18:821–834. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ersahin T, Tuncbag N and Cetin-Atalay R:
The PI3K/AKT/mTOR interactive pathway. Mol Biosyst. 11:1946–1954.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kurundkar D, Srivastava RK, Chaudhary SC,
Ballestas ME, Kopelovich L, Elmets CA and Athar M: Vorinostat, an
HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth
by dampening mTOR signaling pathway in a human xenograft murine
model. Toxicol Appl Pharmacol. 266:233–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shih T and Lindley C: Bevacizumab: An
angiogenesis inhibitor for the treatment of solid malignancies.
Clin Ther. 28:1779–1802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jarkowski A III, Hare R, Loud P, Skitzki
JJ, Kane JM III, May KS, Zeitouni NC, Nestico J, Vona KL, Groman A
and Khushalani NI: Systemic therapy in advanced cutaneous squamous
cell carcinoma (CSCC): The roswell park experience and a review of
the literature. Am J Clin Oncol. 39:545–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sola Biete A, Querol Marruecos J, Manuel
Calvo FA, Fransoy Verger E, Casino Rovirosa A, de Castro Grau JJ,
de Las Heras González M, Aguerri Ramos A, Eito Palacios A, Candal
Veiras C and López Solano MV: Phase II trial: Concurrent
radio-chemotherapy with weekly docetaxel for advanced squamous cell
carcinoma of head and neck. Clin Transl Oncol. 9:244–250. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cartei G, Cartei F, Interlandi G,
Meneghini G, Jop A, Zingone G, Tabaro G and Mazzoleni F: Oral
5-fluorouracil in squamous cell carcinoma of the skin in the aged.
Am J Clin Oncol. 23:181–184. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Roskoski R Jr: ErbB/HER protein-tyrosine
kinases: Structures and small molecule inhibitors. Pharmacol Res.
87:42–59. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ratushny V, Gober MD, Hick R, Ridky TW and
Seykora JT: From keratinocyte to cancer: The pathogenesis and
modeling of cutaneous squamous cell carcinoma. J Clin Invest.
122:464–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Barnes CJ, Bagheri-Yarmand R, Mandal M,
Yang Z, Clayman GL, Hong WK and Kumar R: Suppression of epidermal
growth factor receptor, mitogen-activated protein kinase, and Pak1
pathways and invasiveness of human cutaneous squamous cancer cells
by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther.
2:345–351. 2003.PubMed/NCBI
|
|
41
|
Lewis CM, Glisson BS, Feng L, Wan F, Tang
X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA
and Weber RS: A phase II study of gefitinib for aggressive
cutaneous squamous cell carcinoma of the head and neck. Clin Cancer
Res. 18:1435–1446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
William WN Jr, Feng L, Ferrarotto R,
Ginsberg L, Kies M, Lippman S, Glisson B and Kim ES: Gefitinib for
patients with incurable cutaneous squamous cell carcinoma: A
single-arm phase II clinical trial. J Am Acad Dermatol.
77:1110–1113.e2. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yao M, Shang YY, Zhou ZW, Yang YX, Wu YS,
Guan LF, Wang XY, Zhou SF and Wei X: The research on lapatinib in
autophagy, cell cycle arrest and epithelial to mesenchymal
transition via Wnt/ErK/PI3K-AKT signaling pathway in human
cutaneous squamous cell carcinoma. J Cancer. 8:220–226. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Preneau S, Rio E, Brocard A, Peuvrel L,
Nguyen JM, Quéreux G and Dreno B: Efficacy of cetuximab in the
treatment of squamous cell carcinoma. J Dermatolog Treat.
25:424–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Samstein RM, Ho AL, Lee NY and Barker CA:
Locally advanced and unresectable cutaneous squamous cell
carcinoma: Outcomes of concurrent cetuximab and radiotherapy. J
Skin Cancer. 2014:2845822014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Einspahr JG, Calvert V, Alberts DS,
Curiel-Lewandrowski C, Warneke J, Krouse R, Stratton SP, Liotta L,
Longo C, Pellacani G, et al: Functional protein pathway activation
mapping of the progression of normal skin to squamous cell
carcinoma. Cancer Prev Res (Phila). 5:403–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhao W, Qiu Y and Kong D: Class I
phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta
Pharm Sin B. 7:27–37. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saba NF, Hurwitz SJ, Magliocca K, Kim S,
Owonikoko TK, Harvey D, Ramalingam SS, Chen Z, Rogerio J, Mendel J,
et al: Phase 1 and pharmacokinetic study of everolimus in
combination with cetuximab and carboplatin for recurrent/metastatic
squamous cell carcinoma of the head and neck. Cancer.
120:3940–3951. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Rogers SJ, Box C, Harrington KJ, Nutting
C, Rhys-Evans P and Eccles SA: The phosphoinositide 3-kinase
signalling pathway as a therapeutic target in squamous cell
carcinoma of the head and neck. Expert Opin Ther Targets.
9:769–790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Song G, Ouyang G and Bao S: The activation
of Akt/PKB signaling pathway and cell survival. J Cell Mol Med.
9:59–71. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Raymond E, Tourneau CL, Gatineau M, Delord
JP, Fayette J, Dreyer C, Tijeras-Raballand A, Albert S, Granier M,
Chibaudel B, et al: CAPRA: Safety, efficacy, and translational
biomarkers of weekly everolimus, carboplatin, and paclitaxel as
induction therapy for locally advanced head and neck squamous cell
carcinoma (HNSCC). An Am J Roentgenol. 177:1041–1044. 2013.
|
|
53
|
Lugowska I, Kosełapaterczyk H, Kozak K and
Rutkowski P: Trametinib: A MEK inhibitor for management of
metastatic melanoma. Onco Targets Ther. 8:2251–2259.
2015.PubMed/NCBI
|
|
54
|
Cammareri P, Rose AM, Vincent DF, Wang J,
Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A,
et al: Inactivation of TGFβ receptors in stem cells drives
cutaneous squamous cell carcinoma. Nat Commun. 7:124932016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sun SC: The non-canonical NF-κB pathway in
immunity and inflammation. Nat Rev Immunol. 17:545–558. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Grivennikov SI and Karin M: Dangerous
liaisons: STAT3 and NF-kappaB collaboration and crosstalk in
cancer. Cytokine Growth Factor Rev. 21:11–19. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Schneider G, Henrich A, Greiner G, Wolf V,
Lovas A, Wieczorek M, Wagner T, Reichardt S, von Werder A, Schmid
RM, et al: Cross talk between stimulated NF-kappaB and the tumor
suppressor p53. Oncogene. 29:2795–2806. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Schulzeosthoff K, Ferrari D, Riehemann K
and Wesselborg S: Regulation of NF-kappa B activation by MAP kinase
cascades. Immunobiology. 198:35–49. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dan HC, Cooper MJ, Cogswell PC, Duncan JA,
Ting JP and Baldwin AS: Akt-dependent regulation of NF-{kappa}B is
controlled by mTOR and Raptor in association with IKK. Genes Dev.
22:1490–1500. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kuzbicki L, Lange D, Stanek-Widera A and
Chwirot BW: Different expression of cyclooxygenase-2 (COX-2) in
selected nonmelanocytic human cutaneous lesions. Folia Histochem
Cytobiol. 49:381–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Muranushi C, Olsen CM, Pandeya N and Green
AC: Aspirin and nonsteroidal anti-inflammatory drugs can prevent
cutaneous squamous cell carcinoma: A systematic review and
meta-analysis. J Invest Dermatol. 135:975–983. 2015. View Article : Google Scholar : PubMed/NCBI
|
